ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab Countries (ProstateCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00801996
Recruitment Status : Withdrawn (Closed by Investigator)
First Posted : December 4, 2008
Last Update Posted : May 13, 2016
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
This protocol is designed to collect a small amount of blood and tissue from individuals with prostate cancer for extraction of DNA (genetic material) for the study of the genetic basis of prostate cancer. The study population will include individuals with known prostate cancer and controls without prostate cancer. The study will be conducted in Doha, Qatar at the Hamad Medical Corporation and Weill Cornell Medical College (Qatar). Individuals in the study population will be of Arab descent from Qatar. In this protocol, researchers will survey epidemiologic factors and medical records of patients with prostate cancer in order to study the clinical characteristics of these individuals. The researchers will collect blood and tissue samples to evaluate the genetic characteristics of individuals with prostate cancer. The researchers will also collect blood samples of individuals without prostate cancer to serve as a control. The goal will be to identify genes that are associated with prostate cancer and gene profiles that are associated with differing prognoses in individuals who have prostate cancer.

Condition or disease
Prostate Cancer

Detailed Description:
The study population will include individuals with known prostate cancer and controls without prostate cancer. Individuals in the study population will be of Arab descent from Qatar. In this protocol, researchers will survey epidemiologic factors and medical records of patients with prostate cancer in order to study the clinical characteristics of these individuals. The researchers will collect blood and tissue samples to evaluate the genetic characteristics of individuals with prostate cancer. The researchers will also collect blood samples of individuals without prostate cancer to serve as a control. The goal will be to identify genes that are associated with prostate cancer and gene profiles that are associated with differing prognoses in individuals who have prostate cancer.

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab Countries
Study Start Date : September 2008
Estimated Primary Completion Date : September 2008
Estimated Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Group/Cohort
1. Prostate Cancer

Inclusion Criteria:

  • All study subjects should be able to provide informed consent
  • Males ages 40 years or older
  • Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.
  • Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care
  • Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0

Exclusion Criteria:

• Patient refuses consent

2. Normal Healthy Controls

Inclusion Criteria:

  • All study subjects should be able to provide informed consent
  • Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)
  • Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer

Exclusion Criteria:

  • Individuals with family history of prostate cancer
  • Individuals not deemed in good overall health by the investigator will not be accepted into the study



Primary Outcome Measures :
  1. Identification of single nucleotide polymorphisms (SNPs) in genes associated with prostate cancer in the Qatari population. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Use of gene expression profiles to develop molecular signatures of prostate cancer that are associated with clinical/pathological phenotypes (e.g., tumor grade, histology, disease stage, responsiveness to therapy) [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Blood and tissue will be collected from individuals with prostate cancer. Only blood will be collected from normal controls.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
  • Individuals of Arab descent from Qatari peninsula
  • Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar
Criteria

Inclusion/Exclusion Criteria for Normal Cohort

Inclusion Criteria:

  • All study subjects should be able to provide informed consent
  • Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)
  • Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer

Exclusion Criteria:

  • Individuals with family history of prostate cancer
  • Individuals not deemed in good overall health by the investigator will not be accepted into the study

Inclusion/Exclusion Criteria for Prostate Cohort

Inclusion Criteria:

  • All study subjects should be able to provide informed consent
  • Males ages 40 years or older
  • Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.
  • Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care
  • Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0

Exclusion Criteria:

• Patient refuses consent


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801996


Locations
Qatar
Weill Cornell Medical College - Qatar
Doha, Qatar
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Study Director: Ronald Crystal, MD Weill Medical College of Cornell University

Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT00801996     History of Changes
Other Study ID Numbers: 0806009874
First Posted: December 4, 2008    Key Record Dates
Last Update Posted: May 13, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Weill Medical College of Cornell University:
prostate cancer
genetics

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases